The company plans to sell 1.7 million shares at $86.83, according to TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio.
On CNBC's "Cramer's Stop Trading" segment, he said that many investors thought the secondary offering would put a halt to the recent rally.
However, this stock is "a winner," he reasoned, saying that most doctors who look to prescribe a cannabinoid treatment "have a hard time trusting any other brand" -- making GW Pharmaceuticals stand out.
"This will replace Oxycodone, that's my prediction," Cramer said in regards to pain management via cannabis-related treatments.
GW Pharmaceuticals is "not a penny stock or a marijuana stock," he concluded, it's "a pain-killing company."
-- Written by Bret Kenwell in Petoskey, Mich.